NeuroSense Therapeutics Ltd.

6 clinical trials · Sponsor

Record	Firm	Date
A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease. (NCT06185543)	NeuroSense Therapeutics Ltd.	2023-11-19
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject (NCT05436678)	NeuroSense Therapeutics Ltd.	2022-07-26
A Phase IIb, Multi-Center, Multinational, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS (NCT05357950)	NeuroSense Therapeutics Ltd.	2022-05-31
A Pilot Study to Evaluate the PK Profile of PrimeC-ER Tablets in Healthy Adult Subjects (NCT05232461)	NeuroSense Therapeutics Ltd.	2022-04-08
Ciprofloxacin/Celecoxib Combination in Patients With ALS (NCT04090684)	NeuroSense Therapeutics Ltd.	2019-12-09
Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS (NCT04165850)	NeuroSense Therapeutics Ltd.	2019-11-25

Every clearance here is in the API, with alerts when new ones post.